Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay

• Published in: Viruses Vol. 14; no. 5; p. 1065
• Main Authors: Abravanel, Florence, Parraud, Delphine, Chapuy-Regaud, Sabine, Miedouge, Marcel, Bonnin, Estelle, Larrieu, Margaux, Aversenq, Alexandre, Lhomme, Sébastien, Izopet, Jacques
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 17.05.2022; MDPI
• Subjects: Antibodies; Automation; Communication; Genotype & phenotype; Hepatitis; Hepatitis Antibodies; hepatitis E virus; Hepatitis E virus - genetics; Humans; Immunocompetence; immunocompetent patients; Immunocompromised hosts; immunocompromised patients; Immunoglobulin G; Immunoglobulin M; Immunology; Infections; Life Sciences; Patients; Ribonucleic acid; RNA; Sensitivity and Specificity; Serology; immunocompromised patients; hepatitis E virus; immunocompetent patients; serology
• ISSN: 1999-4915; 1999-4915
• DOI: 10.3390/v14051065

To evaluate the diagnostic performance of the Liaison® Murex anti-HEV IgM and IgG assays running on the Liaison® instrument and compare the results with those obtained with Wantai HEV assays. We tested samples collected in immunocompetent and immunocompromised patients during the acute (HEV RNA positive, anti-HEV IgM positive) and the post-viremic phase (HEV RNA negative, anti-HEV IgM positive) of infections. The specificity was assessed by testing HEV RNA negative/anti-HEV IgG-IgM negative samples. The clinical sensitivity of the Liaison® IgM assay was 100% for acute-phase samples (56/56) and 57.4% (27/47) for post-viremic samples from immunocompetent patients. It was 93.8% (30/32) for acute-phase (viremic) samples and 71%% (22/31) for post-viremic samples from immunocompromised patients. The clinical sensitivity of the Liaison® IgG assay was 100% for viremic samples (56/56) and 94.6% (43/47) for post-viremic samples from immunocompetent patients. It was 84.3% (27/32) for viremic samples and 93.5% (29/31) for post-viremic samples from immunocompromised patients. Specificity was very high (>99%) in both populations. We checked the limit of detection stated for the Liaison® IgG assay (0.3 U/mL). The clinical performance of the Liaison® ANTI-HEV assays was good. These rapid, automated assays for detecting anti-HEV antibodies will greatly enhance the arsenal for diagnosing HEV infections.